Todd Kunkler

home / authors / todd-kunkler

Articles

Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult Choices

Carriers of Mutation Responsible for Multiple Endocrine Neoplasia Can Face Difficult Choices

Todd Kunkler
May 29th 2012

Results of a multi-generational case study strengthen the case for genetic screening in cases of hereditary thyroid cancer.

Read More

Researchers Find Regional Differences in Stage of Presentation and Survival of Individuals With Thyroid Cancer

Researchers Find Regional Differences in Stage of Presentation and Survival of Individuals With Thyroid Cancer

Todd Kunkler
May 29th 2012

Patients are more likely to present with regional or distant metastases and experience lower rates of cancer-free survival depending on where they live.

Read More

Genetic Data Points to Potential New Therapeutic Target for Adrenocortical Carcinoma

Genetic Data Points to Potential New Therapeutic Target for Adrenocortical Carcinoma

Todd Kunkler
May 29th 2012

Researchers find that overexpression of a specific gene is associated with poor survival in patients with adrenocortical carcinoma.

Read More

FDA Approves First Fentanyl Nasal Spray for Breakthrough Cancer Pain

FDA Approves First Fentanyl Nasal Spray for Breakthrough Cancer Pain

Todd Kunkler
July 12th 2011

FDA approvad Lazanda (fentanyl) nasal spray for the management of breakthrough pain in adult cancer patients.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need